262 related articles for article (PubMed ID: 24071060)
1. Is treatment with liraglutide efficient?
Mezquita Raya P; Reyes García R
Endocrinol Nutr; 2014 Apr; 61(4):202-8. PubMed ID: 24071060
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of add-on treatments to metformin in a Swedish setting: liraglutide vs sulphonylurea or sitagplitin.
Steen Carlsson K; Persson U
J Med Econ; 2014 Sep; 17(9):658-69. PubMed ID: 24950434
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
Lorber D
Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
[TBL] [Abstract][Full Text] [Related]
4. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
Gao L; Zhao FL; Li SC
Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
7. [Drug therapy of type 2 diabetes and cardiovascular prevention: potentials for liraglutide].
Reboldi G
G Ital Cardiol (Rome); 2009 Jul; 10(7):434-47. PubMed ID: 19761101
[TBL] [Abstract][Full Text] [Related]
8. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
Lee WC; Conner C; Hammer M
Curr Med Res Opin; 2011 May; 27(5):897-906. PubMed ID: 21348806
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
[TBL] [Abstract][Full Text] [Related]
11. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
Jendle J; Torffvit O; Ridderstråle M; Ericsson Å; Nilsen B; Bøgelund M
J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443
[TBL] [Abstract][Full Text] [Related]
12. The future use of liraglutide: implications of the LEAD-2 study for treatment guidelines in type 2 diabetes.
Gadsby R
Prim Care Diabetes; 2010 Oct; 4(3):139-44. PubMed ID: 20418194
[TBL] [Abstract][Full Text] [Related]
13. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
14. [Liraglutide: a human GLP-1 analogue for the treatment of diabetes mellitus type 2].
Jahn E; Sausele T
Med Monatsschr Pharm; 2009 Nov; 32(11):402-7. PubMed ID: 19947303
[TBL] [Abstract][Full Text] [Related]
15. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of liraglutide in type II diabetes: a systematic review.
Zueger PM; Schultz NM; Lee TA
Pharmacoeconomics; 2014 Nov; 32(11):1079-91. PubMed ID: 25052903
[TBL] [Abstract][Full Text] [Related]
17. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.
Marso SP; Poulter NR; Nissen SE; Nauck MA; Zinman B; Daniels GH; Pocock S; Steinberg WM; Bergenstal RM; Mann JF; Ravn LS; Frandsen KB; Moses AC; Buse JB
Am Heart J; 2013 Nov; 166(5):823-30.e5. PubMed ID: 24176437
[TBL] [Abstract][Full Text] [Related]
18. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide (Victoza) for type 2 diabetes.
Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660
[TBL] [Abstract][Full Text] [Related]
20. Liraglutide - overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes.
Davies MJ; Kela R; Khunti K
Diabetes Obes Metab; 2011 Mar; 13(3):207-20. PubMed ID: 21205109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
